Q-omics provides the consensus-scored ANTXR1 profile across patient tissues and cancer cell-line models. ANTXR1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ANTXR1 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, ANTXR1 RNA expression shows 19,422 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, THCA, and ACC as cancer lineages where ANTXR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANTXR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANTXR1 survival associations across molecular data types. ANTXR1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (10) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANTXR1 RNA expression–survival associations across cancer types. High ANTXR1 expression shows unfavorable associations in UVM, ACC, STAD and THCA, but favorable associations in HNSC and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ANTXR1 RNA expression.
This table summarizes ANTXR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ANTXR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANTXR1 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, KIRC, KIRP and COAD. The THCA box plot shows higher ANTXR1 RNA expression in normal versus tumor tissue (log2 FC = −1.633, t-test p < 0.001).
This table shows molecular features associated with ANTXR1 in patient tissues and cancer cell lines. In patient samples, ANTXR1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANTXR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
